HLA-G and neoplasm: In conclusion, nanobody‐based trispecific T cell engager, Nb‐TriTE, targeting both PD‐L1 and HLA‐G on tumor cells along with CD3ɛ on T cells, offers a promising solution to the shortcomings of monospecific ICP antibodies.